Log in or Sign up for Free to view tailored content for your specialty!
Obesity News
Safety, cost and more: The issues PCPs should consider when prescribing GLP-1s
There are many important factors primary care providers must consider when prescribing popular anti-obesity medications, according to experts.
GLP-1 receptor agonist prescriptions for obesity have risen in those without diabetes
New prescriptions of GLP-1 receptor agonists for the treatment of obesity have increased significantly among individuals without type 2 diabetes in the last decade, according to a study in Annals of Internal Medicine.
Log in or Sign up for Free to view tailored content for your specialty!
Weight-loss surgery appears to benefit patients with heart failure, obesity
In a single-center cohort of patients with heart failure and obesity, weight-loss surgery led to improved clinical outcomes including reduced BMI and HbA1c and less reliance on diuretics, researchers reported.
Top in endocrinology: Tirzepatide vs. semaglutide; FDA rejects icodec for diabetes
Researchers found that adults with overweight or obesity lost more weight with tirzepatide than semaglutide in a head-to-head comparison of the medications using electronic medical records data.
Obesity in young adulthood linked to adverse heart structure, function later in life
People with excess adiposity in young adulthood were more likely to have adverse cardiac structure and function later in life compared with people without it, researchers reported in the European Heart Journal.
Nearly half of cancer deaths among U.S. adults attributable to modifiable risk factors
About 40% of cancer cases and nearly half of cancer deaths among U.S. adults aged 30 years or older can be attributable to modifiable risk factors, according to a study led by American Cancer Society researchers.
Top in endocrinology: Semaglutide linked to optic neuropathy; CGM helps keep HbA1c down
Semaglutide was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy — a form of optic neuropathy that can cause blindness — in adults with type 2 diabetes or obesity, recent data show.
Q&A: Phenotype test predicting semaglutide response could ‘change conversation’ on obesity
In a Healio exclusive, Andres J. Acosta, MD, PhD, highlights data demonstrating that the MyPhenome test may serve as a biomarker to determine whether a patient with obesity will be a “good responder” to semaglutide.
Tirzepatide led to greater real-world weight loss than semaglutide for adults with obesity
Adults with overweight or obesity lost more weight with the GIP/GLP-1 dual agonist tirzepatide than the GLP-1 receptor agonist semaglutide, according to findings published in JAMA Internal Medicine.
Overweight, obesity during young adulthood associated with greater CVD risk later in life
Higher BMI during early adulthood was associated with an elevated risk for CV outcomes, like heart disease and stroke, among adults aged 35 to 70 years, according to a study published in The Lancet Public Health.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read